PARI Pharma - Leading Aerosol Therapies Worldwide

home

about us

creating value

our technologies

pipeline

news & events

studies

site map

Clinical Trials

Posters and Publications

		Articles
		2008
		2007
		2006
		2005
		2004
		2003
		2002
		2001
		2000
		Request Poster/Publication

Note: Not all studies are available based on copyrights of the original documents. Please note the PARI Pharma copyright studies are owned by PARI Pharma. Data may not be referenced in any way including print and electronic formats without the prior written consent of PARI Pharma.

[DDL 11-06 37] E. Bitterle, M. Keller, M. Tservistas, G. Lang, R. Meyers, S. Elbashir, J. DeVincenzo, L. Radesca, J. Cehelsky: Integrity, In-Vitro Activity and Aerosol Delivery Performance of RSV Specific siRNA (ALN-RSV01) Inhalation Solutions Nebulised by an eFlow® Electronic Nebuliser. Drug Delivery to the Lungs 17, Edinburgh, United Kingdom, November 30 –December 1, 2006
[DDL 11-06 36] M. Keller, A. Bucholski, M. Hug, K. Leung, A. Coates: Attempts to Predict Lung Deposition by In-Vitro/In-Vivo Correlation Using Tobramycin Inhalation Solutions and Different Nebuliser Systems as an Example. Drug Delivery to the Lungs 17, Edinburgh, United Kingdom, November 30 –December 1, 2006
DDL 11-06 35] I. Schuschnig, M. Hug, E. Klopfer, M. Knoch, M. Keller: The Next Generation Impactor (NGI): Effect of environmental conditions, impactor temperature and flow rate on particle size measurement of an aerosol using the eFlow® nebuliser. Drug Delivery to the Lungs 17, Edinburgh, United Kingdom, November 30 –December 1, 2006
[DDL 11-06 34] R. Stangl, E. Grieblinger, M. Tservistas: Adapting a Nebulizer for AAT Deficiency Patients with an Emphysema Breathing Pattern. Drug Delivery to the Lungs 17, Edinburgh, United Kingdom, November 30 –December 1, 2006
[NACF 10-06 32] M. Keller, U.Schuschnig, M. Knoch, J. Zimmermann, N. Boden, K.-H. Kullmann, J. Mainz: Characterization of Nebulized PulmozymeÒ Administered by the PARI SINUSä Utilizing a Human Nasal Cast Model. 20^th Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, November 2-5, 2006.
[NACF 10-06 32] M. Keller, U.Schuschnig, M. Knoch, J. Zimmermann, N. Boden, K.-H. Kullmann, J. Mainz: Characterization of Nebulized PulmozymeÒ Administered by the PARI SINUSä Utilizing a Human Nasal Cast Model. 20^th Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, November 2-5, 2006.
[NACF 10-06 31] M. Keller, A. Bucholski, M. Hug, K. Leung, A. Coates: Ways for an In Vitro/In Vivo Correlation for Predicting Lung Deposition of Aqueous Nebulized Tobramycin Formulations Linking Breath Simulation and Cascade Impaction Methods. 20th Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, November 2-5, 2006.
[NACF 10-06 30] M. Keller, S. Bauer, S. Tillmanns, E. Bitterle, M. Tservistas, E. Haltner-Ukomodu: Effect of Alpha-1 Antitrypsin on the Vitality of Calu-3 Cells Representing an Epithelial Bronchial Cell Model and Assessment of Nebulization Efficiency by eFlow®. 20th Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, November 2-5, 2006.
[NACF 10-06 29] E. Bitterle, M. Keller, A. Akkar, K. Steinfuehrer, G. Menges: *Nebulization of a Liposomal Cyclosporin A Formulation by eFlowÒ 30L: Correlation Between In Vitro* and In Vivo Results.** 20th Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, November 2-5, 2006.
[ERS 09-06 26] M. Tservistas, A. Luithlen, M. Hug, M. Keller: Aerosol performance of two Ambroxol inhalation products upon nebulisation by the eFlowÒ rapid and the PARI LC STARÒ. ERS 16^th Annual Congress, Munich, Germany, September 2-6, 2006
[ERS 09-06 25] R. Fischer, A. Bucholski, M. Hug, T. Selzer, M. Luber, Zimmermann: Assessment of the new jet nebulizer platform PARI LCÒ SPRINT designed for different age groups and a faster delivery of aqueous inhalation formulations. ERS 16^th Annual Congress, Munich, Germany, September 2-6, 2006
[ERS 09-06 24] U. Schuschnig, E. Klopfer, M. Luber, T. Selzer, M. Keller: In-Vitro deposition study of levofloxacin solution into a novel human nasal cast model by the PARI VibrENT™. ERS 16^th Annual Congress, Munich, Germany, September 2-6, 2006
[ERS 09-06 23] M. Keller, A. Bucholski, M. Hug: Effect of different nebulizers on the aerosol delivery performance of isotonic disodium cromoglycate (IsoCROM™). ERS 16^th Annual Congress, Munich, Germany, September 2-6, 2006
[ERS 09-06 22] M. Keller, M. Hug, A. Bucholski, T. Gallem, R. Stangl, M. Knoch: Characterization of three inhalation products by the Sofia Anatomical Infant Nose Throat (SAINT) model upon nebulization by the eFlowÒ Baby electronic nebulizer. ERS 16^th Annual Congress, Munich, Germany, September 2-6, 2006
[ERS 09-06 21] M. Tservistas, E. Bitterle, M. Keller, S. Bauer: Aerosol characterization of alpha-1 Antitrypsin after nebulisation with the eFlowÒ, a vibrating membrane nebulizer. ERS 16^th Annual Congress, Munich, Germany, September 2-6, 2006
[ERS 09-06 20] L. Bakuridze, S. Neckermann, V. Andrieu, J.C. Dubus: Are there differences in throat deposition using variable valved holding chambers? ERS 16th Annual Congress, Munich, Germany, September 2-6, 2006
[APS 06-06 15] M. Keller: Pediatric Inhaled Products-An Unmet Challenge for the Industry. APS Inhalation Focus Group Workshop, Loughborough, United Kingdom, June 28, 2006 (oral presentation)
[ECFC 06-06 14] M. Keller, M. Hug, E. Bitterle, A. Bucholski: Reduced Treatment Time for Colistimethate Sodium Solution (Colostin CF) Aerosolised by eFlow® rapid, a Novel Electronic Nebuliser. 29th European CF Conference, Copenhagen, Denmark, June 15-18, 2006 (poster and oral presentation).
[ECFC 06-06 13] U. Schuschnig, E. Klopfer, M. Luber, T. Selzer, H. Mentzel, J. Zimmermann, M. Keller: In-vitro deposition study of a levofloxacin solution aerosolized into a novel human nasal cast model by the PARI SINUS™. 29th European CF Conference, Copenhagen, Denmark, June 15-18, 2006 (poster).
[ECFC 06-06 12] M. Tservistas, A. Gotschlich, A. Bucholski, M. Keller: Nebulization of a novel microbial ,,Quorum Sensing Blocker’’ against Pseudomonas Aeruginosa and Burkholderia cenocepacia by the eFlow® electronic nebuliser. 29th European CF Conference, Copenhagen, Denmark, June 15-18, 2006 (poster).
[ATS 05-06 11] M. Tservistas, S. Bauer, M. Keller, M. Knoch: Protein integrity and activity of Alpha-1-Antitrypsin following nebulization by the eFlow® electronic nebulizer. International Conference of the American Thoracic Society (ATS), San Diego, CA, USA, May 19-24, 2006 (poster).
[ATS 05-06 10] M. Keller, A. Bucholski, M. Hug, T. Selzer, M. Luber, E. Bitterle, R. Fischer, J. Zimmermann: Assessment of the new jet nebulizer platform PARI LC® SPRINT designed for different age groups and a faster delivery of aqueous inhalation formulations. International Conference of the American Thoracic Society (ATS). San Diego, CA, USA May 19-24, 2006 (poster)
[RDD 04-06 09] S. Seemann, L. Weinstein: Satisfying CDRH and FDA’s 510(k) demands for device reliability with a complex electromechanical device: eFlow® Respiratory Drug Delivery (RDD) X, Boca Raton, Florida, USA, April 23-27, 2006 (oral presentation). Proceedings pp. 279-286
[RDD 04-06 08] M. Keller, M. Tservistas, A. Bucholski, M. Hug, M. Knoch: Correlation of laser diffraction and cascade impaction data for aqueous solutions aerosolized by the eFlow® electronic nebulizer. Respiratory Drug Delivery (RDD) X, Boca Raton, Florida, USA, April 23-27, 2006 (poster). Proceedings pp. 745-748.
[RDD 04-06 07] M. Keller, M. Tservistas, E. Bitterle, S. Bauer: Aerosol characterization of alpha-1 Antitrypsin after the nebulization with the eFlow®: A novel vibrating perforated membrane nebulizer. Respiratory Drug Delivery (RDD) X, Boca Raton, Florida, USA, April 23-27, 2006 (poster). Proceedings pp. 733-736.
[RDD 04-06 06] U. Schuschnig, M. Keller, M. Knoch, N. Boden, K.-H. Kullmann: Deposition of Pulmozyme® into the sinus cavities of a human nasal cast model using PARI SINUS™. Respiratory Drug Delivery (RDD) X, Boca Raton, Florida, USA, April 23-27, 2006 (poster). Proceedings pp. 737-740.
[RDD 04-06 04] U. Schuschnig, M. Urbischek, M. Luber, T. Selzer, N. Tiffin, I. Friedrich, M. Keller: Comparison of delivery efficiency in a nasal cast model of fluticasone propionate suspensions and a novel solution aerosolized via the PARI VibrENT. Respiratory Drug Delivery (RDD) X, Boca Raton, Florida, USA, April 23-27, 2006 (poster). Proceedings pp. 741-744.
[RDD 04-06-04] M. Keller, E. Bitterle, M. Tservistas, K. Steinfuhrer, A. Akkar, J. Muller, U. Bock, E. Haltner: Cyclosporine A: Investigation on formulation dependent toxicity in a Calu-3 cell culture model and characterization of aerosols generated by the eFlow® electronic nebulizer. Respiratory Drug Delivery (RDD) X, Boca Raton, Florida, USA, April 23-27, 2006 (poster). Proceedings pp. 729-732
E. Haltner-Ukomadu, M. Keller, A. Akkar, R. Mehrwald, A. Raposo, U. Bock: Calu-3 Cells, a Bronchial Epithelial Cell Model to Assess the Aplicability and Tolerability of Drugs, Excipients and Formulations Designed for Inhalation. 5th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Geneva, Switzerland, March 27-30, 2006 (poster).
[APV 03-06 01] I. Friedrich, S. von Opolski, A. Luithlen, M. Tservistas, M. Keller: Colloidal formulations to improve drug delivery by eFlow®, a new electronic nebuliser. 5th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Geneva, Switzerland, March 27-30, 2006 (poster).
[GPP 03-06 02] S. Tillman, R. Ledermüller, M, Keller: Natriumcromoglycat (DNCG) und Inhalationsysteme in der Therapy von kindlichem Asthma – Zeit für ein Update? 28. Jahrrestagung der Gessellschaft für Püdiatrische Pneumologie (GPP), Frankfurt, March 23-25, 2006 (poster). Atemwegs- und Lungenkrankheiten 32(3): 2006, p. 124 (abstract).
[GPP 03-06 03] S. Tillmann, M. Hug, R. Ledermüller, M, Keller: Verbesserung der Verneblungseffizienz von isotonischer Natriumcromoglicat Lösung (IsoCROM) mit eFlow® 30S und LC® SPRINT versus Micromist®. 28. Jahrrestagung der Gessellschaft für Püdiatrische Pneumologie (GPP), Frankfurt, March 23-25, 2006 (poster). Atemwegs- und Lungenkrankheiten 32(3): 2006, pp. 124-125. (abstract).

» back to top